Jose Molto

Summary

Affiliation: Lluita contra la SIDA Foundation
Country: Spain

Publications

  1. ncbi request reprint Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study
    Jose A Muñoz-Moreno
    Lluita contra la SIDA Foundation, Badalona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 23:1166-75. 2007
  2. ncbi request reprint Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review
    Jose A Muñoz-Moreno
    Lluita Contra la SIDA Foundation Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain
    AIDS Rev 11:103-9. 2009
  3. doi request reprint [Neurocognitive disorders related to human immunodeficiency virus infection]
    Jose A Muñoz-Moreno
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Espana
    Med Clin (Barc) 132:787-91. 2009
  4. doi request reprint Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients
    Jose A Muñoz-Moreno
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 24:1301-7. 2008
  5. doi request reprint Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
    Jose A Muñoz-Moreno
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain
    J Neurovirol 16:208-18. 2010
  6. doi request reprint Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients
    Jose Molto
    Lluita contra Sida Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 15:219-25. 2010
  7. ncbi request reprint Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Germans Trias i Pujol Hospital, Badalona, Spain
    Antivir Ther 11:47-51. 2006
  8. doi request reprint Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS Res Hum Retroviruses 26:1191-6. 2010
  9. doi request reprint Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Ther Drug Monit 32:93-6. 2010
  10. ncbi request reprint The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy
    Eugenia Negredo
    Lluita contra la SIDA, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    AIDS 20:619-21. 2006

Detail Information

Publications48

  1. ncbi request reprint Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study
    Jose A Muñoz-Moreno
    Lluita contra la SIDA Foundation, Badalona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 23:1166-75. 2007
    ....
  2. ncbi request reprint Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review
    Jose A Muñoz-Moreno
    Lluita Contra la SIDA Foundation Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain
    AIDS Rev 11:103-9. 2009
    ..Different recommendations on the assessment of efavirenz-related adverse events are also provided...
  3. doi request reprint [Neurocognitive disorders related to human immunodeficiency virus infection]
    Jose A Muñoz-Moreno
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Espana
    Med Clin (Barc) 132:787-91. 2009
    ..This review describes the disorders related to HIV infection, and comments on possible interventions focused on the protection of neurocognitive functioning in HIV-infected people...
  4. doi request reprint Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients
    Jose A Muñoz-Moreno
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 24:1301-7. 2008
    ..We found differences in neurocognitive functioning in relation to nadir CD4 count in HIV-infected patients. Attention should be given to this value in the management of neurocognitive protection in HIV infection...
  5. doi request reprint Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
    Jose A Muñoz-Moreno
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain
    J Neurovirol 16:208-18. 2010
    ..Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning...
  6. doi request reprint Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients
    Jose Molto
    Lluita contra Sida Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 15:219-25. 2010
    ..We explored a treatment simplification strategy to darunavir/ritonavir 900/100 mg once daily guided by the darunavir virtual inhibitory quotient (vIQ) in patients receiving salvage therapy with darunavir/ritonavir 600/100 mg twice daily...
  7. ncbi request reprint Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Germans Trias i Pujol Hospital, Badalona, Spain
    Antivir Ther 11:47-51. 2006
    ..To assess if enfuvirtide (ENF) increases antiviral activity of a highly active four-drug antiretroviral (ARV) regimen containing lopinavir/ritonavir, efavirenz, lamivudine and tenofovir in ARV-naive, HIV-infected patients...
  8. doi request reprint Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS Res Hum Retroviruses 26:1191-6. 2010
    ....
  9. doi request reprint Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Ther Drug Monit 32:93-6. 2010
    ..Atazanavir Ctroughs were compared between Days 0 and 28. Atazanavir and nevirapine Ctroughs at Day 28 were compared with historical controls receiving either 400 mg atazanavir once daily or 200 mg nevirapine twice daily...
  10. ncbi request reprint The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy
    Eugenia Negredo
    Lluita contra la SIDA, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    AIDS 20:619-21. 2006
    ..Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4...
  11. ncbi request reprint Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Clin Pharmacokinet 47:681-92. 2008
    ..It is coformulated with low doses of ritonavir in order to enhance its pharmacokinetic profile. After oral administration, plasma concentrations of lopinavir can vary widely between different HIV-infected patients...
  12. doi request reprint Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice
    José Ramón Santos
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:129-34. 2009
    ....
  13. pmc Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
    Br J Clin Pharmacol 63:715-21. 2007
    ....
  14. ncbi request reprint Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Spain
    Antivir Ther 9:335-42. 2004
    ..To assess the efficacy and safety of a once-daily antiretroviral regimen in HAART-experienced subjects with long-lasting viral suppression...
  15. pmc Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    PLoS ONE 7:e37442. 2012
    ....
  16. ncbi request reprint Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence
    Carmina R Fumaz
    Lluita contra la SIDA Foundation, HIV Unit Germans Trias i Pujol Hospital, Autonomous University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 38:560-5. 2005
    ..Efavirenz has been associated with neuropsychiatric disorders, although little is known about its long-term toxicity...
  17. ncbi request reprint Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Ther Drug Monit 29:648-51. 2007
    ..Therapeutic drug monitoring may be useful in this setting...
  18. pmc Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Ctra de Canyet, Badalona, Barcelona, Spain
    Antimicrob Agents Chemother 52:3928-32. 2008
    ..We suggest targeting a darunavir vIQ of 1.5 for achieving long-term viral suppression...
  19. doi request reprint Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications
    Eugenia Negredo
    Lluita contra Sida Foundation, Institut de Recerca en Ciències de Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Infect Dis 50:1300-8. 2010
    ..Although antiretroviral therapy improves immune response, some human immunodeficiency virus-infected patients present unsatisfactory CD4 T cell recovery despite achieving viral suppression, resulting in increased morbidity and mortality...
  20. ncbi request reprint Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients
    Echeverria Patricia
    Germans Trias i Pujol University Hospital, Barcelona, Spain
    Curr HIV Res 8:467-70. 2010
    ..The high antiviral potency and low toxicity of saquinavir/ritonavir (SQV/r) prompted us to assess a viable strategy in chronic virologically suppressed HIV-infected patients...
  21. ncbi request reprint Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, and Universidad Autonoma de Barcelona, Spain
    J Antimicrob Chemother 60:436-9. 2007
    ..The objective of this study was to assess the effectiveness and safety of monotherapy with lopinavir/ritonavir as a treatment simplification strategy in HIV-infected patients with viral suppression outside a clinical trial setting...
  22. pmc Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Clinic, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    Antimicrob Agents Chemother 55:326-30. 2011
    ..Although no dose adjustment is required, monitoring darunavir concentrations on an individual basis may give reassurance in this setting...
  23. doi request reprint Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:432-8. 2009
    ..To assess the Efficacy and safety of switching from HAART containing enfuvirtide to raltegravir as a simplification strategy in patients with viral suppression and intolerance to enfuvirtide...
  24. doi request reprint Saquinavir exposure in HIV-infected patients with chronic viral hepatitis
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Antimicrob Chemother 63:992-7. 2009
    ....
  25. doi request reprint Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Antimicrob Chemother 62:784-92. 2008
    ....
  26. ncbi request reprint Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis
    Jose Molto
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Clin Pharmacokinet 46:85-92. 2007
    ..To assess the influence of hepatitis C virus (HCV) co-infection and the extent of liver fibrosis on lopinavir/ritonavir pharmacokinetics in HIV-infected patients without liver function impairment...
  27. doi request reprint Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy
    Josep M Llibre
    Lluita contra la SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Spain
    AIDS 25:1683-90. 2011
    ..With the exception of those cases requiring dose adjustments, the preferential use of FDACs should be recommended for the treatment of HIV-1 infection in those situations when the agents included in the coformulation are drugs of choice...
  28. doi request reprint Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen. Etraswitch Study
    Patricia Echeverria
    Department of HIV, Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Autonomous University of Barcelona, Barcelona, Spain
    PLoS ONE 9:e84676. 2014
    ..It has also shown antiviral efficacy in antiretroviral-naïve patients. However, data on the switching from protease inhibitors (PI) to ETR are lacking...
  29. doi request reprint Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers
    Javier A Estévez
    Pharmacokinetic Pharmacodynamic Modelling and Simulation, Institut de Recerca de l Hospital de la Santa Creu i Sant Pau IIB Sant Pau, Barcelona, Spain
    J Antimicrob Chemother 67:2013-9. 2012
    ..To evaluate the pharmacokinetics, tolerability and safety of 300 mg of atazanavir boosted with 100 or 50 mg of ritonavir, both once daily, at steady state...
  30. pmc Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Clinic, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antimicrob Agents Chemother 56:2837-41. 2012
    ..19) for the concentration at the end of the dosing interval. In summary, coadministration of silymarin with darunavir-ritonavir seems to be safe in HIV-infected patients; no dose adjustment for darunavir-ritonavir seems to be necessary...
  31. ncbi request reprint Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study)
    Eugenia Negredo
    Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Germans Trias i Pujol Hospital, Badalona, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 38:47-52. 2005
    ..To compare the efficacy and safety of a nucleoside-sparing approach with a conventional highly active antiretroviral therapy (HAART) regimen in antiretroviral-experienced patients with prolonged viral suppression...
  32. ncbi request reprint Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects
    Jose Molto
    HIV Clinical Unit Lluita Contra Ia Sida Foundation, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 20:1283-8. 2004
    ..Previous STIs do not influence time off therapy when HAART is definitively discontinued in chronically HIV-infected subjects. CD4 nadir is an important factor in the treatment discontinuation decision...
  33. ncbi request reprint Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins
    Eugenia Negredo
    Lluita contra la SIDA, Germans Trias i Pujol Hospital, Universitat Autonoma de Barcelona, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
    AIDS 20:2159-64. 2006
    ..To assess the efficacy, safety, and pharmacokinetic interactions of ezetimibe in HIV-infected patients with poorly controlled antiretroviral-associated dyslipidaemia while taking pravastatin alone...
  34. doi request reprint Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients
    Jose Molto
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Clin Pharmacokinet 52:543-53. 2013
    ....
  35. pmc Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Clinic, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antimicrob Agents Chemother 56:5328-31. 2012
    ..In conclusion, the coadministration of E. purpurea with etravirine was safe and well tolerated in HIV-infected patients; our data suggest that no dose adjustment for etravirine is necessary...
  36. ncbi request reprint [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice]
    Jose Molto
    Fundación Lluita Contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 26:24-6. 2008
    ..The present review summarizes the main results of the various retrospective studies on LPV/r as a simplification strategy of antiretroviral therapy in daily clinical practice...
  37. ncbi request reprint HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain
    Beatriz Mothe
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Catalonia, Spain
    Curr HIV Res 7:597-600. 2009
    ..Based on our findings, we suggest some recommendations regarding the management of this growing population...
  38. doi request reprint Pulse Wave Velocity as Index of Arterial Stiffness in HIV-Infected Patients Compared With a Healthy Population
    Patricia Echeverria
    Lluita contra la SIDA Foundation, Department of Internal Medicine, Germans Trias i Pujol University Hospital, Autonomous University of Barcelona, Barcelona, Spain and Department of Econometrics, Statistics and Spanish Economy, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 65:50-6. 2014
    ..Chronic HIV infection leads to premature atherosclerosis. Arterial stiffness is considered a subclinical marker of cardiovascular disease...
  39. pmc Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Clinic, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antimicrob Agents Chemother 55:72-5. 2011
    ....
  40. pmc Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antimicrob Agents Chemother 54:3047-8. 2010
    ..5% and 19.1 ml/min in patient 2, respectively. Our results suggest minimal raltegravir removal by hemodialysis with no specific raltegravir dosage adjustments required in HIV-infected patients undergoing hemodialysis...
  41. pmc Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Badalona, Barcelona, Spain
    Br J Clin Pharmacol 62:560-6. 2006
    ....
  42. pmc Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    PLoS ONE 8:e70201. 2013
    ..Data on suppression of HIV replication in the CNS and on the subsequent risk of neurocognitive impairment using monotherapy with boosted protease inhibitors are limited...
  43. doi request reprint Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain
    J Antimicrob Chemother 68:2358-62. 2013
    ..Immune hyperactivation in immunodiscordant patients can induce residual HIV replication and limit CD4 T cell recovery. We assessed the impact of raltegravir intensification on CD4 T cell recovery and viral persistence...
  44. ncbi request reprint Therapeutic drug monitoring of antiretroviral agents scenario
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, University Hospital Germans Trias i Pujol, Barcelona, Spain
    J HIV Ther 9:75-8. 2004
    ..The best method to individualize the dosage regimen has not been identified yet. Finally, participation of different laboratories in external cross-validation programmes is crucial to ensure that results are accurate...
  45. doi request reprint [Use of herbal remedies among HIV-infected patients: patterns and correlates]
    Jose Molto
    Fundació Lluita contra la Sida, Hospital de día de VIH, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana
    Med Clin (Barc) 138:93-8. 2012
    ..To evaluate the prevalence and patterns of use of herbal remedies among HIV-infected patients, and to identify potential health risks and correlates associated with the use of these products...
  46. doi request reprint [Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy]
    Josep M Llibre
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 28:615-20. 2010
    ..Excluding those cases that require a particular dose adjustment, FDCA are a preferred treatment option and their use must be strongly recommended in all scenarios where the components included in the combination are preferred drugs...
  47. ncbi request reprint Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load
    Eugenia Negredo
    Lluita contra la SIDA and Irsicaixa Foundations Germans Trias i Pujol Hospital, Badalona, Spain
    AIDS 18:459-63. 2004
    ..We recently observed a significant CD4 cell count decline in patients receiving didanosine (ddI) 400 mg, tenofovir (TDF) and nevirapine (NVP), despite virological suppression...
  48. doi request reprint Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study
    Cristina Tural
    HIV Clinical Unit, Internal Medicine Department and Fundació de la Lluita contra la SIDA, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 16:833-41. 2011
    ..It is uncertain whether a 4-week induction period of pegylated interferon and ribavirin increases early virological response (EVR) in HIV-HCV-coinfected patients...